Clinical management of concurrent diabetes and tuberculosis and the implications for patient services

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 9, 2014, Pages 740-753

  Riza, Anca Lelia ^a,b   Pearson, Fiona ^c   Ugarte Gil, Cesar ^d,e   Alisjahbana, Bachti ^f   Van de Vijver, Steven ^g,h   Panduru, Nicolae M ^b,i   Hill, Philip C ^j   Ruslami, Rovina ^f   Moore, David ^k   Aarnoutse, Rob ^a   Critchley, Julia A ^c   van Crevel, Reinout ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f PADJADJARAN UNIVERSITY   (Indonesia)

^g AFRICAN POPULATION AND HEALTH RESEARCH CENTER   (Kenya)

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

ⁱ CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^j UNIVERSITY OF OTAGO   (New Zealand)

^k LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; PYRAZINAMIDE; RIFAMPICIN; GLUCOSE BLOOD LEVEL; TUBERCULOSTATIC AGENT;

BLOOD GLUCOSE MONITORING; CLINICAL FEATURE; DIABETES MELLITUS; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DRUG CHOICE; DRUG COST; DRUG SAFETY; GLYCEMIC CONTROL; HEALTH CARE AVAILABILITY; HEALTH CARE DELIVERY; HEALTH ECONOMICS; HEALTH SERVICE; HUMAN; LATENT TUBERCULOSIS; LIFESTYLE MODIFICATION; MANAGED CARE; NEEDS ASSESSMENT; OUTCOME ASSESSMENT; PATIENT EDUCATION; PATIENT MONITORING; PHARMACEUTICAL CARE; PUBLIC HEALTH SERVICE; REVIEW; RISK ASSESSMENT; SCREENING TEST; TUBERCULOSIS; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CHEMOPROPHYLAXIS; DIABETES MELLITUS, TYPE 2; DRUG INTERACTION; GLUCOSE BLOOD LEVEL; HEALTH; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROCEDURES; PROGNOSIS; TUBERCULOSIS, PULMONARY;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; BLOOD GLUCOSE; CHEMOPREVENTION; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; GLOBAL HEALTH; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOCOMPROMISED HOST; PROGNOSIS; TUBERCULOSIS, PULMONARY;

EID: 84908303010     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(14)70110-X     Document Type: Review

References (105)

1. Global tuberculosis report 2013 2013, WHO, World Health Organization, Geneva.
2. Jeon CY, Murray MB Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008, 5:e152.
3. Stevenson CR, Critchley JA, Forouhi NG, et al. Diabetes and the risk of tuberculosis: a neglected threat to public health?. Chronic Illn 2007, 3:228-245.
4. Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med 2011, 9:81.
5. Lönnroth K, Roglic G, Harries AD Improving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practice. Lancet Diabetes Endocrinol 2014, 2:730-739.
6. IDF Diabetes Atlas 2013, IDF, International Diabetes Federation, Brussels. sixth edn.
7. Caminero JA, Sotgiu G, Zumla A, Migliori GB Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010, 10:621-629.
8. IDF Diabetes Atlas 2000, IDF, International Diabetes Federation, Brussels. first edn.
9. Unwin NC, Alberti KG Diabetes and the good, the bad and the ugly of globalization. Int Diabetes Monitor 2007, 19:6-11.
10. An overview of urbanization, internal migration, population distribution and development in the world 2008, United Nations Population Division, United Nations Population Division, New York.
11. Hales CN, Barker DJP Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Int J Epidemiol 2013, 42:1215-1222.
12. Wells JC The thrifty phenotype: An adaptation in growth or metabolism?. Am J Hum Biol 2011, 23:65-75.
13. Unwin N, Whiting D, Roglic G Social determinants of diabetes and challenges of prevention. Lancet 2010, 375:2204-2205.
14. Faurholt-Jepsen D, Range N, Praygod G, et al. Diabetes is a risk factor for pulmonary tuberculosis: a case-control study from Mwanza, Tanzania. PLoS One 2011, 6:e24215.
15. Alavi SM, Khoshkhoy MM Pulmonary tuberculosis and diabetes mellitus: co-existence of both diseases in patients admitted in a teaching hospital in the southwest of Iran. Caspian J Intern Med 2012, 3:421-424.
16. Balakrishnan S, Vijayan S, Nair S, et al. High diabetes prevalence among tuberculosis cases in Kerala, India. PLoS One 2012, 7:e46502.
17. Viswanathan V, Kumpatla S, Aravindalochanan V, et al. Prevalence of diabetes and pre-diabetes and associated risk factors among tuberculosis patients in India. PLoS One 2012, 7:e41367.
18. Goldhaber-Fiebert JD, Jeon CY, Cohen T, Murray MB Diabetes mellitus and tuberculosis in countries with high tuberculosis burdens: individual risks and social determinants. Int J Epidemiol 2011, 40:417-428.
19. Young F, Wotton CJ, Critchley JA, Unwin NC, Goldacre MJ Increased risk of tuberculosis disease in people with diabetes mellitus: record-linkage study in a UK population. J Epidemiol Community Health 2012, 66:519-523.
20. Basoğlu OK, Bacakoğlu F, Cok G, Sayiner A, Ates M The oral glucose tolerance test in patients with respiratory infections. Monaldi Arch Chest Dis 1999, 54:307-310.
21. Oluboyo PO, Erasmus RT The significance of glucose intolerance in pulmonary tuberculosis. Tubercle 1990, 71:135-138.
22. Gearhart MM, Parbhoo SK Hyperglycemia in the critically ill patient. AACN Clin Issues 2006, 17:50-55.
23. Takasu N, Yamada T, Miura H, et al. Rifampicin-induced early phase hyperglycemia in humans. Am Rev Respir Dis 1982, 125:23-27.
24. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivistö KT Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther 2001, 69:400-406.
25. Chang JT, Dou HY, Yen CL, et al. Effect of type 2 diabetes mellitus on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: a potential role in the emergence of multidrug-resistance. J Formos Med Assoc 2011, 110:372-381.
26. Jiménez-Corona ME, Cruz-Hervert LP, García-García L, et al. Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. Thorax 2013, 68:214-220.
27. Reis-Santos B, Locatelli R, Horta BL, et al. Socio-demographic and clinical differences in subjects with tuberculosis with and without diabetes mellitus in Brazil-a multivariate analysis. PLoS One 2013, 8:e62604.
28. Faurholt-Jepsen D, Range N, PrayGod G, et al. Diabetes is a strong predictor of mortality during tuberculosis treatment: a prospective cohort study among tuberculosis patients from Mwanza, Tanzania. Trop Med Int Health 2013, 18:822-829.
29. Viswanathan V, Vigneswari A, Selvan K, Satyavani K, Rajeswari R, Kapur A Effect of diabetes on treatment outcome of smear-positive pulmonary tuberculosis-a report from South India. J Diabetes Complications 2014, 28:162-165.
30. Reed GW, Choi H, Lee SY, et al. Impact of diabetes and smoking on mortality in tuberculosis. PLoS One 2013, 8:e58044.
31. Odone A, Houben RMGJ, Lönnroth K, White RG The effect of diabetes and undernutrition trends on reaching 2035 global tuberculosis targets. Lancet Diabetes Endocrinol 2014, 2:754-764.
32. Al-Quwaidhi AJ, Pearce MS, Sobngwi E, Critchley JA, O'Flaherty M Comparison of type 2 diabetes prevalence estimates in Saudi Arabia from a validated Markov model against the International Diabetes Federation Diabetes Atlas and other modelling studies. Diabetes Res Clin Pract 2014, 103:496-503.
33. Jeon CY, Harries AD, Baker MA, et al. Bi-directional screening for tuberculosis and diabetes: a systematic review. Trop Med Int Health 2010, 15:1300-1314.
34. Cox ME, Edelman D Tests for screening and diagnosis of type 2 diabetes. Clin Diabetes 2009, 27:132-138.
35. Fluorescent light-emitting diode (LED) microscopy for diagnosis of tuberculosis 2007, World Health Organization Press, Geneva. WHO (Ed.).
36. Kumpatla S, Sekar A, Achanta S, et al. Characteristics of patients with diabetes screened for tuberculosis in a tertiary care hospital in South India. Public Health Action 2013, 3:23-28.
37. Steingart KR, Sohn H, Schiller I, et al. Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2013, 1. CD009593.
38. Van't Hoog AH, Langendam MW, Mitchell E, et al. A systematic review of the sensitivity and specificity of symptom- and chest-radiography screening for active pulmonary tuberculosis in HIV-negative persons and persons with unknown HIV status 2013, World Health Organisation, Geneva.
39. Li L, Lin Y, Mi F, et al. Screening of patients with tuberculosis for diabetes mellitus in China. Trop Med Int Health 2012, 17:1294-1301.
40. Lin Y, Li L, Mi F, et al. Screening patients with diabetes mellitus for tuberculosis in China. Trop Med Int Health 2012, 17:1302-1308.
41. Amin S, Khattak MI, Ghulam S, Wazir MN Frequency of pulmonary tuberculosis in patients with diabetes mellitus. Gomal J Med Sci 2011, 9:163-165.
42. Gounder S, Harries AD Screening tuberculosis patients for diabetes mellitus in Fiji: notes from the field. Public Health Action 2012, 2:145-147.
43. Kibirige D, Ssekitoleko R, Mutebi E, Worodria W Overt diabetes mellitus among newly diagnosed Ugandan tuberculosis patients: a cross sectional study. BMC Infect Dis 2013, 13:122.
44. Olayinka A, Yetunde K, Anthonia O Prevalence of diabetes mellitus in persons with tuberculosis in a tertiary health centre in Lagos, Nigeria. Indian J Endocrinol Metab 2013, 17:486-489.
45. Screening of patients with diabetes mellitus for tuberculosis in India. Trop Med Int Health 2013, 18:646-654. India Diabetes Mellitus-Tuberculosis Study Group.
46. Screening of patients with tuberculosis for diabetes mellitus in India. Trop Med Int Health 2013, 18:636-645. India Tuberculosis-Diabetes Study Group.
47. Prakash BC, Ravish KS, Prabhakar B, et al. Tuberculosis-diabetes mellitus bidirectional screening at a tertiary care centre, south India. Public Health Action 2013, 3:18-22.
48. Jaeger S, Karargyris A, Candemir S, et al. Automatic screening for tuberculosis in chest radiographs: a survey. Quant Imaging Med Surg 2013, 3:89-99.
49. Pai M, Zwerling A, Menzies D Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008, 149:177-184.
50. Mansilla Bermejo MJ, Sanz Gil MJ, Moraleda Velasco P, Alvarez Prado A, Carbayo Garcia JJ, Mata Guijarro F Tuberculin test in diabetic patients in a health center. Aten Primaria 1995, 16:154-157. (in Spanish).
51. Vega Torres RA, Conde JG, Díaz M Prevalence of tuberculin reactivity and risk factors for the development of active tuberculosis upon admission to a nursing home. P R Health Sci J 1996, 15:275-277.
52. Nwabudike LC, Ionescu-Tirgoviste C Intradermal reactions to purified protein derivative in patients with diabetes mellitus. Rom J Intern Med 2005, 43:127-132.
53. Lesnichii AV, Karpina LZ Experience with the chemoprophylaxis of pulmonary tuberculosis in diabetes mellitus patients. Probl Tuberk 1969, 47:1-3. (in Russian).
54. Pfaffenberg R, Jahler H Isoniazid & recurrence of tuberculosis in diabetics. Z Tuberk 1958, 111:167-173. (in German).
55. Collaborative framework for care and control of tuberculosis and diabetes 2011, WHO and International Union against TB and Lung Disease, World Health Organization, Geneva.
56. United States Affiliated Pacific Islands-standards for the management of tuberculosis and diabetes Pacific Island TB Controllers Association, (accessed March 1, 2014). http://www.spc.int/tb/component/content/article/75-pacific-standards-for-management-of-tb-and-diabetes.
57. Screening all TB patients for diabetes mellitus: from pilot to policy change International Union of Tuberculosis and Lung Disease, (accessed March 1, 2014). http://old.theunion.org/index.php/en/newsroom/news/item/2310-screening-all-tb-patients-for-diabetes-mellitus-from-pilot-to-policy-change.
58. McCowen KC, Malhotra A, Bistrian BR Stress-induced hyperglycemia. Crit Care Clin 2001, 17:107-124.
59. Kumpatla S, Aravindalochanan V, Rajan R, Viswanathan V, Kapur A Evaluation of performance of A1c and FPG tests for screening newly diagnosed diabetes defined by an OGTT among tuberculosis patients-a study from India. Diabetes Res Clin Pract 2013, 102:60-64.
60. Adepoyibi T, Weigl B, Greb H, Neogi T, McGuire H New screening technologies for type 2 diabetes mellitus appropriate for use in tuberculosis patients. Public Health Action 2013, 3:10-17.
61. WHO and IDF Screening for Type 2 Diabetes. Report of a World Health Organization and International Diabetes Federation meeting 2003, World Health Organization and International Diabetes Federation, Geneva.
62. Echouffo-Tcheugui JB, Ali MK, Griffin SJ, Narayan KM Screening for type 2 diabetes and dysglycemia. Epidemiol Rev 2011, 33:63-87.
63. Waugh N, Scotland G, McNamee P, et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess 2007, 11:1-125.
64. Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg 2009, 80:634-639.
65. Ruslami R, Aarnoutse RE, Alisjahbana B, van der Ven AJ, van Crevel R Implications of the global increase of diabetes for tuberculosis control and patient care. Trop Med Int Health 2010, 15:1289-1299.
66. Chiang CY, Lee JJ, Chien ST, et al. Glycemic control and radiographic manifestations of tuberculosis in diabetic patients. PLoS One 2014, 9:e93397.
67. Alisjahbana B, Sahiratmadja E, Nelwan EJ, et al. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis 2007, 45:428-435.
68. Nijland HMJ, Ruslami R, Stalenhoef JE, et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis 2006, 43:848-854.
69. Ruslami R, Nijland HMJ, Adhiarta IGN, et al. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents Chemother 2010, 54:1068-1074.
70. Requena-Méndez A, Davies G, Ardrey A, et al. Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV. Antimicrob Agents Chemother 2012, 56:2357-2363.
71. van Ingen J, Aarnoutse RE, Donald PR, et al. Why do we use 600 mg of Rifampicin in tuberculosis treatment?. Clin Infect Dis 2011, 52:e194-e199.
72. Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 2013, 13:27-35.
73. Hall RG, Leff RD, Gumbo T Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Pharmacotherapy 2009, 29:1468-1481. the Insights from the Society of Infectious Diseases Pharmacists.
74. Niazi AK, Kalra S Diabetes and tuberculosis: a review of the role of optimal glycemic control. J Diabetes Metab Disord 2012, 11:28.
75. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379. the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD)the European Association for the Study of Diabetes (EASD).
76. Rotchford AP, Rotchford KM, Machattie T, Gill GV Assessing diabetic control-reliability of methods available in resource poor settings. Diabet Med 2002, 19:195-200.
77. Tornio A, Niemi M, Neuvonen PJ, Backman JT Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends Pharmacol Sci 2012, 33:312-322.
78. Sun H, Scott DO Impact of genetic polymorphisms of cytochrome P450 2 C (CYP2C) enzymes on the drug metabolism and design of antidiabetics. Chem Biol Interact 2011, 194:159-167.
79. Cho SK, Yoon JS, Lee MG, et al. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clin Pharmacol Ther 2011, 89:416-421.
80. Salpeter SR, Greyber E, Pasternak GA Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010, 4. Salpeter EE Posthumous, CD002967.
81. Scheen AJ, Paquot N Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab 2013, 39:179-190.
82. Alisjahbana B, van Crevel R, Sahiratmadja E, et al. Diabetes mellitus is strongly associated with tuberculosis in Indonesia. Int J Tuberc Lung Dis 2006, 10:696-700.
83. Executive summary: standards of medical care in diabetes-2014. Diabetes Care 2014, 37(suppl 1):S5-13. American Diabetes Association.
84. Key Messages for TB DM Australian Respiratory Council, (accessed March 1, 2014). http://www.thearc.org.au/TBandDiabetes.aspx.
85. Marais BJ, Lönnroth K, Lawn SD, et al. Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect Dis 2013, 13:436-448.
86. Grant P Management of diabetes in resource-poor settings. Clin Med 2013, 13:27-31.
87. Beran D, Yudkin JS Looking beyond the issue of access to insulin: what is needed for proper diabetes care in resource poor settings. Diabetes Res Clin Pract 2010, 88:217-221.
88. Lawn SD, Campbell L, Kaplan R, Little F, Morrow C, Wood R Delays in starting antiretroviral therapy in patients with HIV-associated tuberculosis accessing non-integrated clinical services in a South African township. BMC Infect Dis 2011, 11:258. the IeDEA-Southern Africa.
89. Hermans SM, Castelnuovo B, Katabira C, et al. Integration of HIV and TB services results in improved TB treatment outcomes and earlier prioritized ART initiation in a large urban HIV clinic in Uganda. J Acquir Immune Defic Syndr 2012, 60:e29-e35.
90. WHO policy on TB infection control in health-care facilities, congregate settings and households 2009, WHO, World Health Organization, Geneva.
91. Govindasamy D, Kranzer K, van Schaik N, et al. Linkage to HIV, TB and non-communicable disease care from a mobile testing unit in Cape Town, South Africa. PLoS One 2013, 8:e80017.
92. Van Rie A, Patel MR, Nana M, et al. Integration and task shifting for TB/HIV care and treatment in highly resource-scarce settings: one size may not fit all. J Acquir Immune Defic Syndr 2014, 65:e110-e117.
93. Mdege ND, Chindove S, Ali S The effectiveness and cost implications of task-shifting in the delivery of antiretroviral therapy to HIV-infected patients: a systematic review. Health Policy Plan 2013, 28:223-236.
94. Callaghan M, Ford N, Schneider H A systematic review of task-shifting for HIV treatment and care in Africa. Hum Resour Health 2010, 8:8.
95. Hirst J, Farmer A, Stevens R, Price C Systematic review and meta-analysis of the accuracy of point-of-care HbA1c tests. PROSPERO: CRD42013006678 (accessed March 1, 2014). http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42013006678.
96. Allain TJ, van Oosterhout JJ, Douglas GP, et al. Applying lessons learnt from the 'DOTS' tuberculosis model to monitoring and evaluating persons with diabetes mellitus in Blantyre, Malawi. Trop Med Int Health 2011, 16:1077-1084.
97. Behforouz HL, Farmer PE, Mukherjee JS From directly observed therapy to accompagnateurs: enhancing AIDS treatment outcomes in Haiti and in Boston. Clin Infect Dis 2004, 38(suppl 5):S429-S436.
98. Lester RT, Ritvo P, Mills EJ, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet 2010, 376:1838-1845.
99. Sullivan T, Ben Amor Y The co-management of tuberculosis and diabetes: challenges and opportunities in the developing world. PLoS Med 2012, 9:e1001269.
100. Khader A, Ballout G, Shahin Y, et al. Treatment outcomes in a cohort of Palestine refugees with diabetes mellitus followed through use of E-Health over 3 years in Jordan. Trop Med Int Health 2014, 19:219-223.
101. Khader A, Farajallah L, Shahin Y, et al. Cohort monitoring of persons with diabetes mellitus in a primary healthcare clinic for Palestine refugees in Jordan. Trop Med Int Health 2012, 17:1569-1576.
102. Fisher EB, Boothroyd RI, Coufal MM, et al. Peer support for self-management of diabetes improved outcomes in international settings. Health Aff (Millwood) 2012, 31:130-139.
103. Mohan V, Deepa R, Deepa M, Somannavar S, Datta M A simplified Indian diabetes risk score for screening for undiagnosed diabetic subjects. J Assoc Physicians India 2005, 53:759-763.
104. Clinical guidelines task force global guideline for type 2 diabetes International Diabetes Federation, (accessed March 1, 2014). http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf.
105. van Crevel R, Dockrell HM TANDEM: understanding diabetes and tuberculosis. Lancet Diabetes Endocrinol 2014, 2:270-272. for the TANDEM Consortium.